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Abstract
Glaucoma, the most frequent optic neuropathy, is a leading cause of blindness worldwide. Death of retinal ganglion cells
(RGCs) occurs in all forms of glaucoma and accounts for the loss of vision, however the molecular mechanisms that cause
RGC loss remain unclear. The pro-apoptotic molecule, Fas ligand, is a transmembrane protein that can be cleaved from the
cell surface by metalloproteinases to release a soluble protein with antagonistic activity. Previous studies documented that
constitutive ocular expression of FasL maintained immune privilege and prevented neoangeogenesis. We now show that
FasL also plays a major role in retinal neurotoxicity. Importantly, in both TNFa triggered RGC death and a spontaneous
model of glaucoma, gene-targeted mice that express only full-length FasL exhibit accelerated RGC death. By contrast, FasL-
deficiency, or administration of soluble FasL, protected RGCs from cell death. These data identify membrane-bound FasL as
a critical effector molecule and potential therapeutic target in glaucoma.
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Introduction
Glaucoma is one of the most common causes of blindness
worldwide and, while there are many different forms of glaucoma
that differ significantly in clinical presentation and disease
progression, they all share a common endpoint which is the loss
of retinal ganglion cells (RGCs) [1]. One of the most common forms
of glaucoma, primary open angle glaucoma, is associated with
increased intraocular pressure. However, patients with low or
normal intraocular pressure can also develop glaucoma, indicating
that mechanisms independent of elevated pressure contribute to the
death of RGCs. In spite of extensive research, the pathobiology of
glaucomaispoorlyunderstood.Recentevidenceindicatesthelossof
RGCs is due to apoptosis [2], nevertheless, the actual molecular
mechanism that triggers apoptosis is controversial.
Data from clinical studies and animal models of induced
elevated intraocular pressure (IOP) support the hypothesis that
there is an inflammatory component to glaucoma and that
TNFa contributes to disease progression. Elevated levels of
TNFa have been detected in the aqueous humor and retinal
layers of glaucoma patients with primary open angle, normal
tension, and exfoliation glaucoma [3][4]. In addition, TNFa
polymorphisms have been associated with primary open angle
glaucoma in Japanese and Chinese populations [5,6]. Develop-
ment of glaucoma also coincided with increased levels of TNFa
and TNFa-inducible genes in laser induced rodent models of
elevated IOP [7][8]. However, in this model, TNFa did not
appear to directly induce cytolysis of RGCs, although it could
be shown to activate microglia [7]. Moreover, a single injection
of TNFa into the vitreous of eyes with normal pressure triggered
the loss of RGCs. Together, these data indicate that ocular
stress, such as elevated intraocular pressure, can trigger the
release of TNFa, which in turn activates microglia to become
neurotoxic for RGCs. However, the direct effector mechanism
responsible for microglia mediated RGC neurotoxicity is not
TNFa.
Fas Ligand (FasL) is one candidate that may link activation of
microglia with the induction of apoptosis in RGCs. Fas Ligand
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17659(FasL) is a 40 kDa type II transmembrane protein of the TNF
family, originally identified by its capacity to induce apoptosis in
Fas receptor positive cells [9] and mediate activation induced
cell death in T cells [10]. FasL is e x p r e s s e db ya c t i v a t e dTc e l l s
and constitutively expressed on ocular tissues where it is thought
to contribute to the immune privileged status of the eye, either
by inducing apoptosis of infiltrating inflammatory cells or by
preventing neoangeogenesis [11]. In addition to its pro-
apoptotic activity, FasL can also induce the release of
proinflammatory cytokines [12,13,14]. Importantly, in a rat
model of heat-shock protein-induced RGC degeneration, FasL+
autoreactive T cells have been implicated in the damage of Fas+
RGCs [15]. By contrast, RGC degeneration in the laser-induced
ocular hypertension models does not appear to involve T cells.
However, other cells of the innate immune system, notably
macrophages and retinal microglia, can express FasL upon
activation [16,17]. Thus FasL+ effector cells could be involved
in T-independent destruction of RGCs. Such a pathogenic role
for FasL appears to be in conflict with its purported role in
immune privilege.
The diverse activities of FasL could result from functional
differences in cell-bound vs soluble forms of the molecule, as is
true for other TNF family members [18,19,20]. Moreover, FasL
can be released from the cell by at least two mechanisms. FasL
can be cleaved from the cell surface by metalloproteinases to
produce a truncated soluble product derived from the
extracellular domain (sFasL) [21]. In addition, cell lines and
activated T cells have been reported to release full-length FasL
in the form of microvesicles [22,23]. Both truncated sFasL and
full-length vesicle-associated FasL can be detected as cell-free
FasL by standard ELISA readouts, leading to some confusion as
to the valency and functional activity of cell-free FasL. There is
considerable data to suggest that murine sFasL is non-apoptotic
and anti-inflammatory, and in some instances, sFasL has even
been shown to antagonize the activity of mFasL. This is in
contrast to an experimental form of FasL that corresponds to
the entire extracellular domain [24,25]. On the other hand,
sFasL bound to extracellular matrix proteins is cytotoxic and
FasL has been localized to the extracellular matrix in the
anterior chamber of the eye [26]. Thus, whether FasL
accumulates in the ocular environment as full-length mFasL
or truncated sFasL, matrix-associated or not, could influence its
functional consequences. Remarkably, the relative levels of full-
length and cleaved FasL in the eye have not been carefully
evaluated.
Most direct functional comparisons of mFasL and sFasL have
been carried out by using transfected cells that express only wild
type FasL, mFasL or sFasL. In the current study, we have used
FasL-deficient mice as well as mice from a gene-targeted line in
which the FasL metalloproteinase cleavage sites were mutated to
prevent cleavage of the membrane-bound protein. We have
compared the ability of these mice to develop RGC degeneration
following intraocular TNFa treatment and in a spontaneous
model of glaucoma. Overall our data reveal a critical neurotoxic
effector function for mFasL and neuroprotective function of
sFasL.
Results
TNFa triggered loss of RGCs is dependent upon FasL
To examine the role of Fas/FasL interactions in the death of
RGCs, we used the intravitreal TNFa injection model developed
by Nakazawa et al (see Figure 1A) [7]. Recipients included a
FasL knockout (KO) line, developed in our laboratory (Figure
S1). As the more commonly used point mutation encoded by the
FasL
gld locus does not completely eliminate Fas receptor
engagement [27]. Groups of wild-type C57BL/6J (WT-B6) and
FasL KO mice were given a single intravitreal injection of TNFa
(1 ng/0.5 ml). As negative controls, mice were either untreated, or
injected with normal saline. At four weeks post injection, retinal
sections were stained with an anti-b-III-tubulin antibody to
identify RGCs (Figure 1 B–E). The number of RGCs was
determined quantitatively in representative retinal sections as
described in the methods (Figure 1F). There was no significant
difference in the number of RGCs between either untreated WT,
WT mice given an intravitreal injection of saline, or untreated
FasL KO mice. Therefore the absence of FasL did not have any
spontaneous effect on the number of RGCs. However, consistent
with previous studies, a single intravitreal injection of TNFa
resulted in a significant loss of RGCs in the WT-B6 mice by four
weeks post TNFa injection. By contrast, there was no loss of
RGCs in TNFa treated FasL KO mice. We conclude from these
experiments that FasL is required for the TNFa triggered loss of
RGCs.
DCS mice express only mFasL and maintain normal
ocular histology
To examine the importance of sFasL in ocular homeostasis and
RGC degeneration, we constructed a membrane-only FasL gene-
targeted mouse in which the FasL metalloproteinase cleavage sites
in exon 2 were mutated (Figure S1). This mouse line was
designated as DCS. WT and DCS mice were tested for expression
of mFasL and sFasL. Cell lysates and culture supernatants
prepared from activated T cells were analyzed by Western blot.
A 38 kDa mFasL band was detected in the WT lysate and a
27 kDa sFasL band was detected in the WT supernatant. By
contrast, cell lysates from the DCS T cells contained more of the
38 kDa mFasL protein and the DCS supernatant contained no
detectable sFasL (Figure 2A). Whole eye lysates were also
prepared from WT and DCS mutant mice to test for ocular
expression of mFasL and sFasL by Western blot (Figure 2B). Two
mFasL bands (38 kD and 34 kD) were detected at low levels in
whole eye lysates from WT mice. As an important specificity
control, both mFasL bands were missing from eye lysates that were
prepared from FasL knockout mice [27]. Therefore, the two bands
most likely represent differential glycosylation, previously reported
for mFasL [24,28,29]. In comparison to WT mice the expression
of both the 38 kD and 34 kD mFasL bands were significantly
increased in DCS mice (Figure 2B and 2C). It is important to
note, that sFasL was not detected by Western blot in the whole
lysates from WT mice, possibly reflecting clearance from the eye
or instability of the soluble form.
Altogether, these data demonstrate that DCS mutant mice
express increased levels of mFasL and no detectable sFasL.
Importantly, the DCS mutant mice display no clinically
detectable spontaneous systemic phenotype. Extensive histologi-
cal studies of ocular tissues did not reveal any detectable
spontaneous eye phenotype in either the anterior or posterior
segment.
Accelerated loss of RGCs in DCS mice
Groups of WT and DCS mice received a single intravitreal
injection of TNFa (1 ng/0.5 ml) and 1 week later mice were
euthanized and the eyes evaluated histologically for RGC
degeneration (Figure 2 D–H). Untreated DCS and WT mice
displayed no significant difference in the number of RGCs,
indicating the DCS mutation had no visible effect on RGC
development in healthy mice. As expected from the previous
FasL Cleavage and Glaucoma
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display any significant loss of RGCs 1 week after administration;
normally a reduction of RGCs in WT mice is not observed until 4
weeks after TNFa treatment. By contrast, there was a significant
reduction in the number of RGCs in DCS mice treated with
TNFa. Moreover, there was a small, but significant reduction in
the number of RGCs in DCS mice that received an intravitreal
saline injection. In this case, RGC loss is most likely due to a
hypersensitive response to the modest release of TNFa that is
triggered by the injection procedure. These data indicate that the
increased expression of mFasL by microglia (or other effector
cells), and/or the absence of sFasL in the ocular microenviron-
ment, results in an accelerated loss of RGCs in response to
TNFa.
To prove the DCS mutation accounted for the accelerated loss
of RGCs via the Fas receptor, we intercrossed DCS mice with Fas-
deficient lpr mice. B6/129
DCS/DCS lpr/lpr and wild type littermates
expressing normal FasL and Fas were given intravitreal injections
of either TNFa or normal saline. One week post TNFa injection,
RGC degeneration was evaluated histologically. In Fas-deficient
DCS mice, TNFa was unable to trigger the loss of RGCs
(Figure 2I). Together these data prove that the accelerated loss of
RGCs in TNFa injected DCS mice is dependent upon the Fas/
FasL pathway.
Loss of nerve fibers in the retina of DCS mice
Glaucoma is characterized not only by the loss of RGCs, but
also by the loss of the their axons. The axonal loss is often
visualized clinically as slit-like or wedge-shape defects in the retinal
nerve fiber layer. To evaluate the effect of FasL triggered RGC
death on axonal integrity, we examined the nerve fiber layer of
WT and DCS mice in retinal whole mounts (see diagram in
Figure 1A). There was no significant difference between the nerve
fiber layers of WT and DCS mice that were either uninjected
Figure 1. FasL is required for the loss of RGCs following TNFa injection. (A) Diagram of the cross section of an eye demonstrating: an
intravitreal TNFa injection; the layers of the retina (ILM- inner limiting membrane, GCL- ganglion cell layer, INL- inner nuclear layer, ONL- outer nuclear
layer); a retinal whole mount stained to identify the nerve fiber layer. (B–E) WT C57BL/6 or FasL KO mice were untreated or received intravitreal
injections of saline or TNFa. Eyes were enucleated at 4 weeks and RGCs were identified in retinal sections using an anti-bIII-tubulin antibody (green)
and TOPRO (blue nuclear stain). (F) All bIII-tubulin positive RGCs were counted in each retinal section and the average number RGCs per retinal
section was calculated (10 sections per eye). N=10 per treatment group. (* P,0.05).
doi:10.1371/journal.pone.0017659.g001
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(data not shown). Moreover, WT mice treated with TNFa
displayed a normal nerve fiber layer one week after treatment
that was not significantly different from the untreated controls
(Figure 3C). By contrast, at 1 week after treatment, the TNFa-
treated DCS mice displayed a significant loss of nerve fibers
(Figure 3D), with some mice displaying very few intact axons
(Figure 3E). Axonal loss in the TNFa treated DCS mice was
abrogated in B6/129
DCS/DCS lpr/lpr mice that lacked a functional
Fas receptor (Figure 3F). These data demonstrate that DCS mice
exhibit accelerated loss of both the soma and axon in response to
TNFa.
Figure 2. Loss of RGCs in DCS mice is dependent upon the Fas/FasL pathway. All Western blots displayed are representative of three
independent experiments: (A) CD3 activated T cell lysates and supernatants, (B) whole eye lysates from individual eyes of: WT, DCS, and FasL KO mice,
(C) densitometry of eye lysate Western blots (* and ** P,0.05), (D–G) WT or DCS mice received an intravitreal injection of saline, or TNFa. Retinal
sections were obtained 7 days later and RGCs were stained with bIII-tubulin. Arrow heads highlight the loss of RGCs. (H) All bIII-tubulin positive RGCs
were counted in each retinal section (5 sections per eye; 10 eyes per group) and the average number RGCs per retinal section was calculated. (I) WT or
DCS6lpr mice received intravitreal injections of saline, or TNFa. The number of RGCs was determined 7 days later in retinal sections. Green=Beta
tubulin III and blue=nuclear stain. N=10 per treatment group. (* p.0.05).
doi:10.1371/journal.pone.0017659.g002
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DCS mice
We and others demonstrated previously that mFasL is
proinflammatory and proapoptotic, while sFasL is anti-inflamma-
tory and non-apoptotic [24]. To determine whether administra-
tion of recombinant sFasL could prevent the loss of RGCs in
TNFa treated DCS mice, DCS mice received an intravitreal
injection of either sFasL alone (100 ng), TNFa alone (1 ng), or
both sFasL and TNFa. At 7 days post injection, the eyes were
evaluated for axonal degeneration in retinal whole mounts. No
significant loss of nerve fibers was observed in either WT, or DCS
mice treated with sFasL alone as compared with untreated WT
Figure 3. The loss of retinal ganglion cell nerve fibers is accelerated in DCS mice. WT, DCS, or DCS6lpr mice were either untreated, or
received intravitreal TNFa. Seven days later the nerve fibers in retinal whole mounts were stained with SMi32 (anti-neurofilament antibody) and
examined by confocal microscopy. (A) untreated WT retina, (B) untreated DCS retina, (C) WT+TNFa treated retina, (D and E) DCS+TNFa treated retina,
(F) DCS6lpr+TNFa treated retina. Asterisks mark the optic nerve head, Red=SMi32, and blue=nuclear stain. The pictures presented are
representative of individual mice (N=10 for each group).
doi:10.1371/journal.pone.0017659.g003
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nerve fibers was observed at 7 days post TNFa treatment in DCS
mice compared to the untreated control mice (Figure 4A, 4C).
However, intravitreal injection of recombinant soluble Fas ligand
together with TNFa prevented the loss of nerve fibers (Figure 4E).
It is important to note that the mouse recombinant sFasL used in
these experiments corresponds with the physiological cleavage
product (Pro 132 to Leu 279) and has weak or no cytolytic activity
against A20 target cells.
Spectral domain optical coherence tomography (SD-OCT)
provides a noninvasive method to assess the thickness of the retinal
nerve fiber layer [30]. In the clinic, the retinal nerve fiber layer
thickness is an essential measure for objective glaucoma assessment
[31,32]. However, the use of SD-OCT to measure the retinal
nerve fiber layer thickness in the mouse is a relatively new area of
investigation. In the current study, SD-OCT was used to assess the
retinal nerve fiber layer thickness prior to enucleation and
preparation of retinal whole mounts. Sectorial areas containing
retinal defects were identified in retinal whole mounts stained with
SMI32 (quadrant #1 in Figure 4A, 4C, and 4E). The
corresponding retinal areas were identified in the OCT-based en-
face fundus reconstruction and nerve fiber thickness was assessed
as described in the methods (Figure 4B, 4D, and 4F). SD-OCT
measurements indicated a significant thinning of the nerve fiber
layer in TNFa treated, but not TNFa+sFasL treated mice
(Figure 4G). These data indicate that sFasL can block the
neurotoxic effects of membrane FasL and prevent nerve fiber loss
in DCS mice. Moreover, these date indicate that SD-OCT can be
used as a non-invasive method to assess retinal nerve fiber layer
thickness in mice.
Retinal microglia express mFasL
Retinal tissue from TNFa treated WT and DCS mice were
examined by immuno-histochemical staining for Fas and FasL to
confirm that Fas+ target cells were present within the ganglion cell
layer and to determine which cell types were potential FasL
effector cells. As expected, Fas was highly expressed in the
ganglion cell layer and the level of Fas was similar in TNFa treated
WT and DCS mice (Figure 5A).
In contrast to Fas, FasL was expressed at much higher levels in
DCS mice as compared to WT mice. Moreover, the most intense
staining was observed in the ganglion cell layer, with some staining
also observed in the inner nuclear layer (Figure 5B). Double
staining for microglia (Iba1) and astrocytes (GFAP) clearly
demonstrated that FasL expression in the ganglion cell layer was
primarily restricted to retinal microglia (Figure 5C) and
minimally, if at all, in astrocytes (Figure 5D). These data indicate
that DCS retinal microglia express higher than normal levels of
mFasL and/or that greater numbers of FasL+ microglial cells
accumulate in the TNF-treated DCS retinae [33].
RGCs are susceptible to mFasL induced apoptosis
We verified that the Fas+ human retinal ganglion cell line,
RGC5, was susceptible to mFasL induced apoptosis using mFasL
expressing microvesicles (Figure S2). To determine whether
TNFa treatment of DCS mice triggered apoptosis of RGCs in
vivo, DCS and WT mice were treated with TNFa and at 24 hrs
post injection histological sections were stained with TUNEL and
examined for apoptotic cells. No apoptotic cells were detected in
sections from untreated WT or untreated DCS mice (data not
shown). In addition, little to no apoptosis was observed in saline
treated WT and DCS mice. However, a significant number of
apoptotic cells were detected in the retinal ganglion cell layer of
TNFa treated DCS mice (Figure 5 E, F). Together these data
support the hypothesis that TNFa activated retinal microglia
express mFasL that triggers apoptosis of Fas receptor positive
RGCs.
mFasL induced retinal degeneration in a spontaneous
model of glaucoma
DBA/2 mice spontaneously develop age-related elevated
intraocular pressure due to mutations in the Gpnmb and Tyrp1
genes that trigger iris stromal atrophy and pigment dispersion,
respectively. This results in closure of the iridocorneal angle and
elevated IOP by approximately 6–8 months of age, followed by the
loss of RGCs and nerve fibers between 11 and 15 months [34,35].
To determine if mFasL also accelerates RGC degeneration in this
spontaneous model of glaucoma, we backcrossed the DCS
mutation onto the DBA/2J background. The 5th generation
backcross mice were intercrossed to obtain DCS/DCS mice
(DBA/2J- DCS), and a WT/WT littermate control group (DBA/
2J-wt). Both the DBA/2J-wt and DBA/2J- DCS mice developed
high intraocular pressure with age (Figure 6A), pigment
dispersion (Figure 6B), an enlarged anterior chamber
(Figure 6C), and angle closure (Figure 6D). The appearance
of these symptoms was not significantly different from fully
backcrossed DBA/2J mice as reported previously [34,35]. Thus
the failure to cleave FasL in DBA/2J- DCS mice did not
ameliorate these glaucoma-inducing phenotypes.
However, while there was no detectable loss of nerve fibers in 5
month old DBA/2J-wt mice, there was marked thinning of the
nerve fibers in the DBA/2J- DCS mice (Figure 6E arrows),
indicative of accelerated loss of axons. Previous extensive analysis
of 12 month old DBA/2J mice by Jakobs and coworkers indicated
that elevated intraocular pressure coincided with loss of only
RGCs; no other retinal neurons were affected [36]. This is evident
from the loss of cells in the ganglion cell layer in 12 month old
DBA/2J-wt mice (Figure 6F, arrows). Unexpectedly, when the
DBA/2J- DCS mice reached 12 months of age, they displayed not
only a greater loss of ganglion cells and nerve fibers, but also
extensive retinal degeneration in all layers of the retina
(Figure 6F). This was not due to the presence of the DCS
mutation alone, since 10 month old DCS B66129 mice displayed
normal retinal architecture and no loss of RGCs. Together, these
data indicate that in a spontaneous elevated intraocular pressure
model of glaucoma, mFasL is also highly neurotoxic.
Discussion
Fas ligand is a potent pro-apoptotic molecule expressed by
cytotoxic effector T and NK cells that is known for its ability to
eliminate virally infected target populations, tumor cells, and
autoreactive T and B cells [11]. However, persistent expression of
FasL by Fas-deficient T cells in mice with Fas+ non-T cell
populations can result in graft-vs-host-like disease [37], total
elimination of wild type lymphocytes [38], or can even cause
pulmonary fibrosis [39]. In addition, FasL has also been shown to
rapidly induce the production of proinflammatory cytokines by a
variety of Fas+ cell types and to promote T lymphocyte activation
[13]. Therefore it is not surprising that expression of FasL on T
and NK cells is tightly regulated either at the transcriptional level
[40], by sequestration in cytoplasmic vesicles [41], or by
metalloprotease cleavage [13].
Remarkably, in contrast to T cells and NK cells, FasL is
constitutively expressed at sites of immune privilege, such as the
eye. Ocular expression of FasL is thought to be required for the
maintenance of immune privilege by limiting ocular inflamma-
FasL Cleavage and Glaucoma
PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17659Figure 4. sFasL protects retinal ganglion cell nerve fibers in DCS mice. DCS mice were either untreated, or received intravitreal: TNFa (1 ng)
alone, or TNFa+sFasL. Seven days later SD-OCT measurements were made and subsequently the nerve fibers in retinal whole mounts were stained
with Smi32 (anti-neurofilament antibody). Displayed are a low power composite montage photograph of the entire Smi32 stained retina and a higher
power (620 magnification) of quadrant #1 (Q1). (A) untreated, (C) TNFa alone, and (E) TNFa+sFasL. Asterisks (*) indicate areas where retinas were
dissected. Arrows highlight nerve fiber thinning. Pictures are representative of a single mouse from each group (N=10 per group). The quadrant #1
was identified in the OCT en-face fundus reconstruction in (B) untreated, and (D) TNFa alone, and (F) TNFa+sFasL. Six sections within the quadrant
were chosen and the nerve fiber thickness measured at two points in each section (identified by an X). A single OCT retinal section and the
corresponding nerve fiber measurements are displayed. (G) A summary of the OCT measurements for each group (N=3 per group; two experiments
performed). (* p.0.05).
doi:10.1371/journal.pone.0017659.g004
FasL Cleavage and Glaucoma
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17659tion [42] and/or neoangeogenesis [43]. Consistent with this
notion, FasL deficient mice develop a more severe inflammatory
response in a murine model of acquired ocular taxoplasmosis
[44]. Natural expression of ocular FasL (i) promotes engraftment
of allogeneic corneal transplants by inducing apoptosis of
infiltrating Fas+ activated T cells [42], and (ii) prevents suture
induced neovascularization by inducing apoptosis of vascular
endothelial cells [45]. By contrast, FasL-deficient mice present
with increased corneal graft rejection and suture induced
neovascularization [45,46]. More recent studies, however, reveal
an apparent paradox in FasL function within the ocular
environment, where ocular expression of membrane-bound FasL
actually promotes immunoreactivity. For example: (i) over
expression of non-cleavable FasL in the cornea triggers
accelerated transplant rejection [47], and (ii) tumor cells that
express a membrane-only form of FasL induce a severe ocular
inflammatory response [48] Moreover, a number of studies have
shown that the soluble form of FasL antagonizes the functional
outcome of membrane-bound FasL [24,25,49], while others
reported that sFasL could bind to ocular matrix proteins and
thereby acquire potent apoptotic activity [26]. Thus it is unclear
how immune privileged sites regulate FasL activity and control its
potentially dangerous effects related to inflammation and
apoptosis of host tissues.
As previously documented [50] and confirmed in the current
report, whether or not a mouse either fails to express FasL, or over
expresses membrane-bound FasL, does not appear to affect ocular
development or normal lymphocyte homeostasis. Since numerous
cell types in the eye constitutively express Fas, the functional
outcome of Fas engagement must be constrained, either by
cytokines present in the ocular microenvironment, such as TGFb
[51], and/or by some other mechanism. Based on our character-
ization of the DCS mFasL mice, we propose that cleavage of the
membrane form of FasL is a critical factor in the regulation of
ocular FasL activity in the immune privileged environment of the
eye.
Figure 5. Expression of Fas and FasL in the neural retina of WT and DCS mice. Frozen retinal sections were prepared from WT and DCS mice
that were either (i) untreated, or (ii) received a prior (7 days) intravitreal injection of TNFa. (A) Fas receptor expression using an anti Fas antibody (Red)
and TOPRO (blue nuclear stain). (B) FasL expression using an anti FasL antibody (red) and TOPRO (blue nuclear stain). Identically treated retinal
sections from FasL KO mice were used as a negative control. (C) Double staining for microglia (Iba1-green) and FasL (red) revealed retinal microglia
(arrowhead) express FasL. (D) Double staining for astrocytes (GFAP-red) and FasL (green) revealed retinal astrocytes (arrowhead) were FasL negative.
(E) Representative TUNEL staining in DCS mice at 24 hours post TNFa injection. Red=TUNEL, Blue=nuclear stain. GCL- ganglion cell layer; INL- inner
nuclear layer; ONL- outer nuclear layer. (F) Percentages of TUNEL positive cells in the retina. (N=5 per group). (* p.0.05). See also Figure S2.
doi:10.1371/journal.pone.0017659.g005
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PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e17659Figure 6. mFasL induced retinal degeneration in DBA/2J mice. The DCS mutation was backcrossed to DBA/2J mice (DBA/2J-DCS) and
compared with littermate controls (DBA/2J-WT). (A) intraocular pressure (IOP) (N$10 mice per group; mean +/2 SEM). DBA/2J-WT and DBA/2J-DCS
(12 mons old) were compared with young (4 mons old) DBA/2J mice for: (B) pigment dispersion and iris atrophy, (C) size of the anterior chamber, and
(D) H&E sections of the iridocorneal angle revealing pigment laden cells (arrow) blocking the aqueous outflow pathway. (E) retinal whole mounts
stained with Smi32 (anti-neurofilament antibody); arrows identify thinning of the nerve fibers. (F) H&E stained retinal sections from: B66129 DCS mice
(10 mons old), DBA/2J-WT (12 mons old), and DBA/2J-DCS (12 mons old). The pictures presented are representative of individual mice in each group
(N=10).
doi:10.1371/journal.pone.0017659.g006
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in the eye, little is known about the extent of cleavage. Cell-free
FasL has been identified by ELISA in the ocular fluids of the eye
[52,53]. However, the ELISA assay can not distinguish cleaved
sFasL from full-length FasL released from the cell in the form of
microvesicles [22]. These studies have been further confounded by
irrelevant cross-reactivities of many of the commercially available
FasL-specific antibodies. In the current study we rigorously
compared whole cell lysates from wild type, DCS, and FasL KO
mice for FasL expression using a highly specific anti-peptide rabbit
antiserum for Western blot analysis [24]. The DCS mFasL mice
express a gene-targeted form of FasL in which the major cleavage
sites were mutated to render the molecule resistant to metallo-
proteinases. While we were able to distinguish clearly two bands
corresponding to full-length FasL in lysates from DCS mice, we
could barely detect a comparable band in lysates derived from wild
type mice. Thus it appears that most ocular FasL is cleaved under
normal physiological conditions. Our inability to detect sFasL in
the eye lysates from WT mice may reflect increased clearance or
instability of the soluble form.
There is general agreement that RGCs die via apoptosis in
glaucoma, although the molecular events underlying RGC loss are
still debated. The participation of glial cells in the death of RGCs
was demonstrated in work from Nakazawa and colleagues linking
increased intraocular pressure with a rapid upregulation of retina-
associated TNFa and subsequent activation of microglia in the
optic nerve head [7]. While both TNFa and activated microglia
were required for the death of RGCs, the direct cytotoxic effector
mechanism remained unclear. TNFa is detected by 2 receptors;
engagement of TNFR1 is thought to trigger apoptosis and
engagement of TNFR2 is thought to trigger the Akt signaling
cascade and promote survival. TNFR2-deficient, but not TNFR1-
deficient mice fail to exhibit RGCs loss following experimentally
induced elevated intraocular pressure or TNFa injection,
consistent with the premise that TNFa indirectly promotes RGC
death [7]. A potential role for FasL, another TNF family member,
in glaucoma was suggested by immunohistological examination of
the retina in a rat model of glaucoma indicating an increased
expression of FasL on microglia in the glaucomatous retina [17].
In the current study we clearly demonstrate that FasL-deficient
mice are resistant to TNFa-triggered loss of RGCs subsequent to
intravitreal injection. Moreover, TNFa treated DCS mice
displayed a more rapid loss of retinal ganglion cells and nerve
fibers (1 week in DCS mice versus 4 weeks in wild type mice). Our
observations were not limited to TNFa treated mice. Using the
spontaneous DBA/2J model of glaucoma [35], we again observed
a significant increase and acceleration in the loss of RGCs and
nerve fibers in mice expressing the DCS mutation. Unexpectedly,
we also observed a dramatic degeneration in all layers of the retina
in 12 month old DBA/2J-DCS mice. While it is generally accepted
that retinal damage in glaucoma patients is restricted to the
ganglion cells, there are reports of damage to other types of retinal
cells [54]. Taken together, these studies establish the membrane-
bound form of FasL as a key neurotoxic effector molecule in
glaucoma and suggest that cleavage of FasL is important in
protecting retinal tissue from extensive degeneration.
Based on our immunohistological examination of the retina, we
further concluded that FasL expression in the retina was
predominantly associated with microglial cells and not astrocytes.
Prior studies had demonstrated that brain microglia express FasL
[55], and therefore it was not surprising to find that retinal
microglial cells also expressed FasL. In addition, the neurotoxic
effects of FasL in the brain had been previously described in a
model of chronic idiopathic demyelinating polyneuropathy, where
macrophage-mediated demyelination was shown to be dependent
upon FasL mediated death of Schwann cells [56]. Together these
data support the hypothesis that RGC-neurotoxic FasL is
expressed by retinal microglia. Whether the increased expression
of FasL in the retina of TNFa treated mice reflects increased
migration of FasL+ microglial cells to the retina and/or increased
level of FasL expression/cell remains to be determined. Letellier et
al recently demonstrated that FasL triggers migration of Fas+
macrophages and neutrophils into the site of spinal cord injury via
activation of the Syk kinase [33]. Importantly, the increased
migration triggered via FasL resulted in increased inflammation
and tissue damage at the injury site, indicating that FasL triggered
migration is a new mechanism by which FasL can trigger
destructive inflammation. Whether FasL triggered migration is
due to the membrane and/or soluble form of FasL is unknown.
Our data also have important implications for the role of sFasL
in glaucoma. The most straightforward explanation for the
accelerated loss of RGCs in DCS versus WT mice is that greater
expression of membrane-bound FasL causes more extensive RGC
death. However, we also found that sFasL could antagonize the
activity of mFasL and, in the context of glaucoma, be
neuroprotective. The opposing activities of membrane and soluble
FasL further suggest that FasL cleavage is a major mechanism for
limiting the neurotoxic activity of FasL in the eye and raises the
intriguing possibility that TNFa may in fact regulate FasL
cleavage. The cleavage of FasL is mediated primarily by MMPs
(MMP7 and MMP3) as well as TIMPs that are the major
endogenous regulators of MMP activities [57]. Both MMPs and
TIMPs are expressed by retinal microglia, RGCs, and their axons
[58]. Therefore, changes in MMP and/or TIMP expression
triggered by TNFa or other factors induced by elevated IOP may
be critical in regulating the ratio of soluble to membrane FasL
expressed by microglia during glaucoma. In conclusion, our data
indicate the enhancement of FasL cleavage and/or forced
expression of sFasL may have therapeutic applications in
preventing RGC apoptosis in glaucoma.
Materials and Methods
Ethics Statement
All animals were treated according to the Association for
Research in Vision and Ophthalmology Resolution on the Use of
Animals in Research. The Schepens IACUC committee approved
all procedures under protocols #S223-1211 and # S230-0312.
Animals
To examine the importance of sFasL in ocular homeostasis and
RGC degeneration, we constructed a FasL-deficient mouse line
(designated as FasL KO) and a membrane-only FasL gene-
targeted mouse line (this cleavage site deleted-mouse line was
designated as DCS). The details of how these mice were produced
are described in the supplemental data (Figure S1). The DCS
founder mice were crossed to C57BL/6 mice for one generation
and then intercrossed for the TNFa studies. Wild-type littermates
were used as WT controls. A second group of mice were
backcrossed to DBA/2J mice (Jackson Laboratories), and then
intercrossed for in vivo analysis. Assessment of the DCS6DBA/2J
and wild-type DBA/2J littermates was performed at the fifth
generation backcross. FasL knockout mice were described
previously [27].
Intravitreal injections
The intravitreal injection, just posterior to the limbus-parallel
conjunctival vessels, were described previously. Mice received a
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(1 ng/0.5 mL of sterile saline) or saline alone. Some mice received
recombinant murine soluble FasL alone (R & D Systems) (100 ng/
0.5 ml sterile physiological saline) or in combination with the
TNFa (100 ng sFasL/1 ng TNFa/0.5 ml sterile physiological
saline). The mouse recombinant sFasL corresponds with the
physiological cleavage product (Pro 132 to Leu 279) and has weak
or no cytolytic activity against A20 target cells.
Quantitation of retinal ganglion cells
Enucleated eyes were fixed and cryostat sections (8 mm) sections
were blocked in 2.5% BSA/0.3% triton in PBS, followed by
incubation with a RGC specific primary antibody, anti-bIII-
tubulin (TU-20, Millipore), a biotinylated secondary antibody, and
Cy2-conjugated streptavidin (Jackson Immuno research). Nuclei
were counterstained with To-pro-3 (Molecular Probes). The total
number of b-III-tubulin/To-Pro-3 double positive retinal ganglion
cells were counted throughout the entire RGC layer of each
section. A total of 10 sections were analyzed per eye (10 eyes
analyzed per group). The sections were taken through the central
globe of each eye.
Retinal whole mounts
Neural retina was isolated, fixed, and incubated with an anti-
neurofilament antibody (SMi32, Covance) for 3 days at 4uC
followed by a Rhodamine (TRITC)-conjugated secondary anti-
body for 2 days at 4uC. Nuclei were counter stained with To-Pro-3
(Molecular Probes, Eugene, OR). Following staining, the retinas
were mounted RGC layer side up and examined by confocal
microscopy (Leica Microsystems; Wetzlar, Germany).
Western blots
Protein lysates were prepared from whole eyes (excluding the
lens) and splenic T cells stimulated with plate-bound anti-CD3.
Proteins were separated on 12% Tris-glycine gels (Invitrogen,
Carlsbad, CA), and transferred onto polyvinylidene difluoride
membranes (Invitrogen, Carlsbad, CA). The membranes were
probed for Fas ligand using a polyclonal rabbit anti-Fas ligand
antibody [24] followed by a goat anti-rabbit-HRP secondary
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). L5178Y-R
tumor transfectants served as positive controls for membrane and
soluble FasL.
Immunofluorescent staining
Immunofluorescent staining was performed on frozen retinal
cross sections using primary antibodies to astrocytes (Cy3-
conjugated GFAP, Jackson ImmunoResearch), microglia (Iba1,
Santa Cruz Technology Inc), FasL (C178 and N20, Santa Cruz
technology Inc), and Fas receptor (C20 Santa Cruz technology
Inc). The secondary antibody for Iba1, FasL, and Fas was a Cy3-
conjugated anti-rabbit. In all cases, isotyped matched antibodies
served as negative controls and To-Pro-3 (Molecular Probes,
Eugene, OR) was used to stain all nucleated cells.
SD-OCT (Spectral Domain Optical Coherence Tomogr-
aphy). Optical coherence tomography was performed using a SD-
OCT system (Bioptigen Inc., Durham, NC) at day 7 after intravitreal
TNFa injection. A volume analysis was performed, using 100
horizontal, raster, and consecutive B-scan lines, each one composed
by 1200 A-scans. The volume size was1.661.6 cm. The software was
able to generate the en-face fundus image using the reflectance
information obtained from the OCT sections (volume intensity
projection), so that the point-to-point correlation between OCT and
fundus position was possible and accurate.
In vivo quantification of retinal nerve fiber layer
thickness. Sectorial areas containing retinal defects were
identified in the retinal whole mount images and the
corresponding retinal areas were identified in the OCT-based
en-face fundus reconstruction. This was achieved by aligning the
two images using the retinal vessels shape and position. Within the
OCT images passing through these areas, six sections from each
eye were randomly chosen and used by a masked operator to
assess the retinal nerve fiber layer thickness. For the meas-
urements, the caliper tool provided by the Bioptigen software was
used in 2 different, and randomly chosen positions on the same
image. The retinal nerve fiber layer thickness was defined as the
interval between the inner and outer boundary of the most
internal retinal hyper-reflective layer visualized in the OCT image.
Measurement was avoided in OCT points that corresponded to
retinal vessels.
RGC apoptosis
Apoptotic cells were identified in 8 mm frozen retinal sections
using a TUNEL In Situ Cell Death detection Kit (TMR red,
Roche Applied Science) and sections were mounted using DAPI
pan-nuclear stain (Vectashield). Following staining, the ratio of
TUNEL positive to total DAPI positive cells was calculated in 6
visual fields at 1006 magnification. These calculations were
repeated in 3 sections per experimental eye with at least 5 animals
per group per time point.
Intraocular (IOP) measurements
IOP was measured using a TonoLab tonometer (Colonial
Medical Supply, Espoo, Finland) and performed as previously
described [34].
Statistics
Where normally distributed, the data were analyzed with an
unpaired t test with a P value of ,0.05 as the basis for rejection of
the null hypothesis. Statistical analysis and graphing were
performed using Microsoft Excel.
Supporting Information
Figure S1 Production of the mutant mice. (A) Targeting
vectors designed to delete the 2 cleavage sites (AA 124/125 and
AA 127/128) located in exon 2 [59,60] were constructed from a
129/OLA P1 genomic clone (Genomesystems Inc, St. Louis) and
used to transfect 129 ES cells. Appropriately targeted cells were
subsequently transfected with the pMC-Cre expression vector to
remove the neo cassette [62]. (B) In the Cre-FasL construct, 8
residues (121–128) were deleted from exon 2. This mutation
resulted in a splicing error and frameshift mutation, thereby
creating a FasL-deficient strain, referred to in the text as FasL KO.
By contrast, the DCS construct replaced the 4 residues that bracket
the 2 potential cleavage sites (designated by the asterisks in the 4
black boxes). These exchange mutations (124SerRThr, 125PHeRLeu,
127LysRArg, and 128GlnRAsn) eliminated the cleavage sites within
the full-length protein and prevented the cleavage of FasL to
produce the soluble form of FasL. (C) RNA was isolated from
activated CD8+ T cells from FasL KO, heterozygous, and wild-
type mice. RT-PCR was performed using primers (designated by
arrows) to amplify the region spanning exon 1, exon 2, and exon 3.
The results demonstrated that wild-type mice expressed a 473 bp
fragment indicating all 3 exons are present, while knockout mice
expressed only a 427 bp fragment indicating the loss of exon 2. As
expected, the heterozygous mice expressed both products. (D)
CD8+ T cells were isolated from the spleen and lymph node of:
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cells were activated with anti-CD3, and analyzed for FasL
expression by FACS analysis. Activated CD8+ T cells from wild-
type mice displayed significant levels of FasL, while heterozygous
mice displayed a significant reduction in FasL. Activated CD8+ T
cells from FasL KO mice displayed no detectable staining over the
isotype control antibody, indicating no FasL was expressed on
these cells. Similar data was obtained with activated CD4+ T cells
(data not shown). (E) Phenotypically, the FasL knock-out mice
present with significantly greater splenomegally and lymphade-
nopathy than gld/gld mice.
(TIF)
Figure S2 Apoptosis of RGCs is induced by mFasL in
vitro. RGC5 cells were differentiated in a 96 well microplates
(1.5610
3 cells per well) as previously described [61]. After
differentiation the media was removed and complete DMEM
was added. Control vesicles or mFasL vesicles prepared as
previously described [13] were added at various dilutions to
differentiated RGC5 cells and at incubated at 37uC for 16 hours.
Cell viability was assessed using the standard 3-[4,5-dimethylthia-
zol-2-yl]-2,5-diphenyltetrazolium (MTT) reduction assay. (A) The
immortalized RGC-5 cell line was differentiated in vitro and
treated with microvesicles expressing membrane-only FasL
(mFasL) or no FasL (neo) at increasing concentrations 1:100,
1:20, 1:7. The MTT cytotoxicity assay was used to measure
viability and revealed significant loss of viability only in RGCs
incubated with mFasL microvesicles. * p.0.05 and ** p.0.01 as
compared to media alone.
(TIF)
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